These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 19433570)

  • 21. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.
    Garonzik SM; Li J; Thamlikitkul V; Paterson DL; Shoham S; Jacob J; Silveira FP; Forrest A; Nation RL
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3284-94. PubMed ID: 21555763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate.
    Imberti R; Cusato M; Accetta G; Marinò V; Procaccio F; Del Gaudio A; Iotti GA; Regazzi M
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4416-21. PubMed ID: 22687507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous colistin use for infections due to MDR Gram-negative bacilli in critically ill paediatric patients: a systematic review and meta-analysis.
    Karageorgos SA; Bassiri H; Siakallis G; Miligkos M; Tsioutis C
    J Antimicrob Chemother; 2019 Sep; 74(9):2497-2506. PubMed ID: 31049586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria.
    Kristoffersson AN; Rognås V; Brill MJE; Dishon-Benattar Y; Durante-Mangoni E; Daitch V; Skiada A; Lellouche J; Nutman A; Kotsaki A; Andini R; Eliakim-Raz N; Bitterman R; Antoniadou A; Karlsson MO; Theuretzbacher U; Leibovici L; Daikos GL; Mouton JW; Carmeli Y; Paul M; Friberg LE
    Clin Microbiol Infect; 2020 Dec; 26(12):1644-1650. PubMed ID: 32213316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration.
    Karaiskos I; Friberg LE; Galani L; Ioannidis K; Katsouda E; Athanassa Z; Paskalis H; Giamarellou H
    Int J Antimicrob Agents; 2016 Sep; 48(3):337-41. PubMed ID: 27474468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients.
    Athanassa ZE; Markantonis SL; Fousteri MZ; Myrianthefs PM; Boutzouka EG; Tsakris A; Baltopoulos GJ
    Intensive Care Med; 2012 Nov; 38(11):1779-86. PubMed ID: 22810779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic Characteristics and Limited Sampling Strategies for Therapeutic Drug Monitoring of Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections.
    Kim EJ; Oh J; Lee K; Yu KS; Chung JY; Hwang JH; Nam EY; Kim HS; Kim M; Park JS; Song KH; Kim ES; Song J; Kim HB
    Ther Drug Monit; 2019 Feb; 41(1):102-106. PubMed ID: 30299430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosing of colistin-back to basic PK/PD.
    Bergen PJ; Li J; Nation RL
    Curr Opin Pharmacol; 2011 Oct; 11(5):464-9. PubMed ID: 21835694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates.
    Nakwan N; Usaha S; Chokephaibulkit K; Villani P; Regazzi M; Imberti R
    Pediatr Infect Dis J; 2016 Nov; 35(11):1211-1214. PubMed ID: 27276179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Shedding light on the use of colistin: still gaps to be filled].
    Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.
    Landersdorfer CB; Nguyen TH; Lieu LT; Nguyen G; Bischof RJ; Meeusen EN; Li J; Nation RL; McIntosh MP
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.
    Dalfino L; Puntillo F; Mosca A; Monno R; Spada ML; Coppolecchia S; Miragliotta G; Bruno F; Brienza N
    Clin Infect Dis; 2012 Jun; 54(12):1720-6. PubMed ID: 22423120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis.
    Liu D; Zhang J; Liu HX; Zhu YG; Qu JM
    Int J Antimicrob Agents; 2015 Dec; 46(6):603-9. PubMed ID: 26607337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacokinetics and Outcomes of Critically Ill Pediatric Patients Treated with Intravenous Colistin at Higher Than Recommended Doses.
    Antachopoulos C; Geladari A; Landersdorfer CB; Volakli E; Ilia S; Gikas E; Gika H; Sdougka M; Nation RL; Roilides E
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.
    Menna P; Salvatorelli E; Mattei A; Cappiello D; Minotti G; Carassiti M
    Chemotherapy; 2018; 63(1):35-38. PubMed ID: 29334366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Colistin in critically ill patients.
    Boisson M; Gregoire N; Couet W; Mimoz O
    Minerva Anestesiol; 2013 Feb; 79(2):200-8. PubMed ID: 23241733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study.
    Markou N; Fousteri M; Markantonis SL; Zidianakis B; Hroni D; Boutzouka E; Baltopoulos G
    J Antimicrob Chemother; 2012 Oct; 67(10):2459-62. PubMed ID: 22790220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration.
    Karvanen M; Plachouras D; Friberg LE; Paramythiotou E; Papadomichelakis E; Karaiskos I; Tsangaris I; Armaganidis A; Cars O; Giamarellou H
    Antimicrob Agents Chemother; 2013 Jan; 57(1):668-71. PubMed ID: 23147733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy.
    Schmidt JJ; Strunk AK; David S; Bode-Böger SM; Martens-Lobenhoffer J; Knitsch W; Scherneck S; Welte T; Kielstein JT
    J Antimicrob Chemother; 2019 Apr; 74(4):997-1002. PubMed ID: 30624668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.